Universitatsklinikum Essen
Universitatsklinikum Essen
Essen, Germany4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety of HRX215 in Patients After Minor and Major Liver Resection | Colorectal Carcinoma Liver Metastases; Liver Resection | Recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT06638502 | |
| Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-05-28 | NCT05422222 | |
| A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Graves Ophthalmopathy, Graves disease, autoimmune disease, disease of orbital part of eye adnexa, endocrine system disorder, exophthalmos, eye disorder, goiter, hereditary disease, hyperthyroidism, immune system disorder, thyroid gland disorder | Active, not recruiting | Phase 3 | 2026-05-22 | NCT06812325 | |
| Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Enrolling by invitation | Phase 3 | 2026-04-29 | NCT05844449 |